JP2008500999A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008500999A5 JP2008500999A5 JP2007513941A JP2007513941A JP2008500999A5 JP 2008500999 A5 JP2008500999 A5 JP 2008500999A5 JP 2007513941 A JP2007513941 A JP 2007513941A JP 2007513941 A JP2007513941 A JP 2007513941A JP 2008500999 A5 JP2008500999 A5 JP 2008500999A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- alkylcarbonyl
- compound
- halogen
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 150000001875 compounds Chemical class 0.000 claims 15
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical class 0.000 claims 10
- 229910052739 hydrogen Inorganic materials 0.000 claims 10
- 239000001257 hydrogen Substances 0.000 claims 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 8
- 125000003118 aryl group Chemical group 0.000 claims 7
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 7
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 125000000623 heterocyclic group Chemical group 0.000 claims 7
- 125000004043 oxo group Chemical group O=* 0.000 claims 6
- 230000007170 pathology Effects 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- -1 benzoimidazolyl Chemical group 0.000 claims 5
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 5
- 150000003254 radicals Chemical class 0.000 claims 5
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims 4
- 150000002431 hydrogen Chemical group 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 125000002971 oxazolyl group Chemical group 0.000 claims 4
- 125000000335 thiazolyl group Chemical group 0.000 claims 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 3
- 238000004519 manufacturing process Methods 0.000 claims 3
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 claims 2
- 206010020571 Hyperaldosteronism Diseases 0.000 claims 2
- 125000005085 alkoxycarbonylalkoxy group Chemical group 0.000 claims 2
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 229960000890 hydrocortisone Drugs 0.000 claims 2
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 2
- 125000001041 indolyl group Chemical group 0.000 claims 2
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 201000009395 primary hyperaldosteronism Diseases 0.000 claims 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 2
- 125000000168 pyrrolyl group Chemical group 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 230000003276 anti-hypertensive effect Effects 0.000 claims 1
- 125000004429 atom Chemical group 0.000 claims 1
- 125000003354 benzotriazolyl group Chemical group N1N=NC2=C1C=CC=C2* 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 1
- 125000002883 imidazolyl group Chemical group 0.000 claims 1
- 230000000297 inotrophic effect Effects 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 230000002503 metabolic effect Effects 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 125000003373 pyrazinyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 230000002285 radioactive effect Effects 0.000 claims 1
- 125000001424 substituent group Chemical group 0.000 claims 1
- 0 C*1C*(*C(*)(*NC2)C3CCCCCC3)N2C(*)(*)CC1 Chemical compound C*1C*(*C(*)(*NC2)C3CCCCCC3)N2C(*)(*)CC1 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CH9162004 | 2004-05-28 | ||
| CH11572004 | 2004-07-09 | ||
| PCT/EP2005/052418 WO2005118541A2 (en) | 2004-05-28 | 2005-05-27 | Heterocyclic compounds and their use as aldosterone synthase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008500999A JP2008500999A (ja) | 2008-01-17 |
| JP2008500999A5 true JP2008500999A5 (enExample) | 2008-07-10 |
Family
ID=34993240
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007513941A Pending JP2008500999A (ja) | 2004-05-28 | 2005-05-27 | 複素環式化合物およびアルドステロンシンターゼ阻害薬としてのそれらの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20080076794A1 (enExample) |
| EP (1) | EP1748986B1 (enExample) |
| JP (1) | JP2008500999A (enExample) |
| AR (1) | AR050251A1 (enExample) |
| AT (1) | ATE490241T1 (enExample) |
| BR (1) | BRPI0510412A (enExample) |
| CA (1) | CA2568164A1 (enExample) |
| DE (1) | DE602005025110D1 (enExample) |
| IL (1) | IL179409A0 (enExample) |
| TW (1) | TW200608978A (enExample) |
| WO (1) | WO2005118541A2 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1960991A (zh) * | 2004-05-28 | 2007-05-09 | 斯皮德尔实验股份公司 | 用作醛固酮合酶抑制剂的四氢咪唑并[1,5－a]吡啶衍生物 |
| TW200716105A (en) * | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Imidazole compounds |
| AR056888A1 (es) * | 2005-12-09 | 2007-10-31 | Speedel Experimenta Ag | Derivados de heterociclil imidazol |
| EP1842543A1 (en) | 2006-04-05 | 2007-10-10 | Speedel Pharma AG | Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist |
| TW200808812A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| TW200808813A (en) * | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| EP1886695A1 (en) * | 2006-06-27 | 2008-02-13 | Speedel Experimenta AG | Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist |
| MX2011012628A (es) | 2009-05-28 | 2011-12-14 | Novartis Ag | Derivados amino-propionicos sustituidos como inhibidores de neprilisina. |
| ES2582395T3 (es) | 2009-05-28 | 2016-09-12 | Novartis Ag | Derivados aminobutíricos sustituidos como inhibidores de neprilisina |
| JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
| US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
| US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
| PL2729142T3 (pl) | 2011-07-08 | 2018-10-31 | Novartis Ag | Sposób leczenia miażdżycy tętnic u osobników z wysokim poziomem triglicerydów |
| UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
| JP6295277B2 (ja) | 2013-02-14 | 2018-03-14 | ノバルティス アーゲー | Ｎｅｐ（中性エンドペプチダーゼ）阻害剤としての置換ビスフェニルブタン酸ホスホン酸誘導体 |
| TW201536814A (zh) | 2013-07-25 | 2015-10-01 | Novartis Ag | 用於治療心臟衰竭之合成環狀多肽 |
| PE20160991A1 (es) | 2013-07-25 | 2016-10-15 | Novartis Ag | Bioconjugados de polipeptidos de apelina sintetica |
| WO2016116842A1 (en) | 2015-01-23 | 2016-07-28 | Novartis Ag | Synthetic apelin fatty acid conjugates with improved half-life |
| JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
| UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
| UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
| JP7657151B2 (ja) | 2018-11-27 | 2025-04-04 | ノバルティス アーゲー | 代謝性障害の処置のためのプロタンパク質コンバターゼスブチリシン／ケキシン９型（ｐｃｓｋ９）阻害剤としての環状ペプチド |
| US20230089867A1 (en) | 2018-11-27 | 2023-03-23 | Novartis Ag | Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder |
| TW202333563A (zh) | 2021-11-12 | 2023-09-01 | 瑞士商諾華公司 | 用於治療疾病或障礙之二胺基環戊基吡啶衍生物 |
| AR127698A1 (es) | 2021-11-23 | 2024-02-21 | Novartis Ag | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |
| KR20260015867A (ko) | 2023-05-24 | 2026-02-03 | 노파르티스 아게 | 질환 또는 장애 치료용 나프티리디논 유도체 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4859691A (en) * | 1987-07-08 | 1989-08-22 | Ciba-Geigy Corporation | Certain 1,2-benzisoxazole derivatives |
| GB8820730D0 (en) * | 1988-09-02 | 1988-10-05 | Erba Carlo Spa | Substituted 5 6 7 8-tetrahydroimidazo/1.5-a/pyridines & process for their preparation |
| US5057521A (en) * | 1988-10-26 | 1991-10-15 | Ciba-Geigy Corporation | Use of bicyclic imidazole compounds for the treatment of hyperaldosteronism |
| DE69012653T2 (de) * | 1989-06-05 | 1995-02-09 | Daiichi Seiyaku Co | Heterocyclische Triazin- oder Triazolo-Verbindungen mit Serotonin 2-Rezeptor-Antagonisten-Wirkung. |
| JP3170273B2 (ja) * | 1989-06-05 | 2001-05-28 | 第一製薬株式会社 | 縮合トリアジン誘導体及びその中間体 |
| CA2026792A1 (en) * | 1989-11-01 | 1991-05-02 | Michael N. Greco | (6,7-dihydro-5h-pyrrolo[1,2-c]imidazol-5-yl)- and (5,6,7,8-tetrahydroimidazo[1,5-a]pyridin-5-yl) substituted 1h-benzotriazole derivatives |
| JPH07503242A (ja) * | 1992-01-27 | 1995-04-06 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | アロマターゼ阻害剤としてのピロロイミダゾリルおよびイミダゾピリジニル置換１ｈ−ベンズイミダゾール誘導体 |
| JPH0971586A (ja) * | 1995-09-07 | 1997-03-18 | Yamanouchi Pharmaceut Co Ltd | 新規な二環性縮合イミダゾール誘導体 |
| JP2004536082A (ja) * | 1999-10-22 | 2004-12-02 | グラクソ グループ リミテッド | ｉｎｖｉｖｏイメージング |
| US20030083342A1 (en) * | 2002-08-27 | 2003-05-01 | Steele Ronald Edward | Combination of organic compounds |
-
2005
- 2005-05-27 AT AT05749325T patent/ATE490241T1/de not_active IP Right Cessation
- 2005-05-27 DE DE602005025110T patent/DE602005025110D1/de not_active Expired - Fee Related
- 2005-05-27 US US11/597,615 patent/US20080076794A1/en not_active Abandoned
- 2005-05-27 AR ARP050102198A patent/AR050251A1/es unknown
- 2005-05-27 CA CA002568164A patent/CA2568164A1/en not_active Abandoned
- 2005-05-27 TW TW094117479A patent/TW200608978A/zh unknown
- 2005-05-27 BR BRPI0510412-2A patent/BRPI0510412A/pt not_active IP Right Cessation
- 2005-05-27 EP EP05749325A patent/EP1748986B1/en not_active Expired - Lifetime
- 2005-05-27 WO PCT/EP2005/052418 patent/WO2005118541A2/en not_active Ceased
- 2005-05-27 JP JP2007513941A patent/JP2008500999A/ja active Pending
-
2006
- 2006-11-20 IL IL179409A patent/IL179409A0/en unknown